PTLA - Portola Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.89
-1.06 (-3.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close29.95
Open30.85
Bid0.00 x 800
Ask0.00 x 800
Day's Range28.71 - 29.85
52 Week Range14.81 - 37.95
Volume826,874
Avg. Volume1,145,812
Market Cap1.974B
Beta (3Y Monthly)2.48
PE Ratio (TTM)N/A
EPS (TTM)-4.54
Earnings DateNov 5, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents

    Edited Transcript of PTLA earnings conference call or presentation 7-Aug-19 8:30pm GMT

    Q2 2019 Portola Pharmaceuticals Inc Earnings Call

  • Here's Why Portola Pharmaceuticals (NASDAQ:PTLA) Can Afford Some Debt
    Simply Wall St.

    Here's Why Portola Pharmaceuticals (NASDAQ:PTLA) Can Afford Some Debt

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • PR Newswire

    Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 1,205,357 shares from Portola at the public offering price. Goldman Sachs & Co. LLC, Citigroup, Cowen, and William Blair are acting as joint book-running managers.

  • Benzinga

    The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down ...

  • PR Newswire

    Portola Pharmaceuticals Announces Proposed Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA)  today announced plans to offer, subject to market and other conditions, $200 million of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional $30 million of its common stock in connection with the offering. All of the shares of common stock in the offering will be sold by Portola Pharmaceuticals.

  • Why Portola Pharmaceuticals Is Rocketing 10.9% Higher Today
    Motley Fool

    Why Portola Pharmaceuticals Is Rocketing 10.9% Higher Today

    The company's second-quarter revenue is sparking optimism for future growth.

  • Portola Pharmaceuticals Inc (PTLA) Q2 2019 Earnings Call Transcript
    Motley Fool

    Portola Pharmaceuticals Inc (PTLA) Q2 2019 Earnings Call Transcript

    PTLA earnings call for the period ending June 30, 2019.

  • Portola Pharmaceuticals (PTLA) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Portola Pharmaceuticals (PTLA) Reports Q2 Loss, Tops Revenue Estimates

    Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 12.38% and 17.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    - Second Quarter Revenues of $28.4 Million ; Andexxa® Net Product Revenues Grow to $27.1 Million - - Launched Ondexxya® (andexanet alfa) with First Orders in Europe - - U.S. Centers for Medicare and Medicaid ...

  • Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View
    Zacks

    Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

    Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

  • Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
    Zacks

    Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

    Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.

  • Zoetis (ZTS) Looks Good: Stock Adds 7.6% in Session
    Zacks

    Zoetis (ZTS) Looks Good: Stock Adds 7.6% in Session

    Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

  • Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance
    Zacks

    Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance

    Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.

  • PR Newswire

    Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe

    SOUTH SAN FRANCISCO, Calif., Aug. 6, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced the Company's first sales of Ondexxya® (andexanet alfa) in Europe. Portola is executing a phased launch of Ondexxya in Europe, with an initial focus on Germany, Austria, the United Kingdom, the Netherlands, Sweden, Denmark and Finland, where Factor Xa inhibitor use, and related bleeds, are among the highest in Europe.

  • PR Newswire

    U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa

    SOUTH SAN FRANCISCO, Calif., Aug. 5, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has increased the maximum reimbursement amount for the New Technology Add-on Payment (NTAP) granted in October 2018 to Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] from 50 percent to 65 percent. The final rule concerning the Hospital Inpatient Prospective Payment System and CMS Fiscal Year 2020 was pre-published online Friday, August 2, 2019 (pages 420-422)  (https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-16762.pdf), and will be formally published in the Federal Register on Friday, August 16, 2019. "Today's CMS decision supports the breakthrough innovation of Andexxa and the clinical value of rapidly reversing the anticoagulant effects of the Factor Xa inhibitors rivaroxaban and apixaban in the event of life-threatening or uncontrolled bleeding," said Scott Garland, Portola's president and chief executive officer.

  • Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
    PR Newswire

    Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

    SOUTH SAN FRANCISCO, Calif. , July 17, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial ...

  • Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors
    PR Newswire

    Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors

    SOUTH SAN FRANCISCO, Calif., July 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced new in vitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and rivaroxaban and the ability of four-factor prothrombin complex concentrate (4F-PCC) to correct inhibition of thrombin generation, compared with warfarin anticoagulation reversal by 4F-PCC. Results showed that, while effective in reversing inhibition of thrombin generation in plasma from patients treated with warfarin, 4F-PCCs did not appear to have an effect on the inhibition of thrombin generation by apixaban or rivaroxaban unless the Factor Xa inhibitor concentration was less than 75 ng/mL.

  • Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
    PR Newswire

    Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

    SOUTH SAN FRANCISCO, Calif., June 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with relapsed/refractory follicular lymphoma (FL) receiving cerdulatinib alone or in combination with rituximab. Data were presented this month in a poster session at the 24th Congress of the European Hematology Association (EHA) in Amsterdam (June 13-16) and during an oral session today at the 15th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (June 18-22).

  • Markit

    See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

    Portola Pharmaceuticals Inc NASDAQ/NGS:PTLAView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for PTLA with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PTLA. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PTLA are favorable, with net inflows of $2.34 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire

    Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., May 28, 2019 -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer,.

  • What’s Portola’s Growth Strategy for Fiscal 2019?
    Market Realist

    What’s Portola’s Growth Strategy for Fiscal 2019?

    Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)European market launchOn April 26, Portola Pharmaceuticals (PTLA) issued a press release announcing conditional marketing authorization granted by the European Commission to

  • How Is Portola’s Andexxa Placed in the First Quarter?
    Market Realist

    How Is Portola’s Andexxa Placed in the First Quarter?

    Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Reimbursement and accessIn its first quarter earnings conference call, Portola Pharmaceuticals (PTLA) highlighted the stocking of Andexxa by 300 hospitals in the US with a